White superficial onychomycosis is an infection of the nail plate by fungus, primarily affecting the surface of the nail. : 305

See also
Onychomycosis
Skin lesion


== References ==
In making this decision, the FDA considered the potential risks associated with the drug, the life-threatening and debilitating nature of the disease, and the lack of available therapies.The application for viltolarsen was granted priority review designation and the FDA granted the approval to NS Pharma, Inc.

Society and culture
Economics
Viltolarsen costs around US$733,000 per year for a person that weighs 30 kilograms (66 lb). References
Further reading
Dhillon S (July 2020). "Viltolarsen: First Approval". Drugs. 80 (10): 1027–1031. doi:10.1007/s40265-020-01339-3. PMID 32519222. S2CID 219542850. Dzierlega K, Yokota T (June 2020). "Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy". Gene Ther. 27 (9): 407–416. doi:10.1038/s41434-020-0156-6. PMID 32483212. S2CID 219157034. Hwang J, Yokota T (October 2019). "Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies". Expert Rev Mol Med. 21: e5. doi:10.1017/erm.2019.5. PMID 31576784. S2CID 203641010. Roshmi RR, Yokota T (October 2019). "Viltolarsen for the treatment of Duchenne muscular dystrophy". Drugs Today. 55 (10): 627–639. doi:10.1358/dot.2019.55.10.3045038. PMID 31720560. S2CID 207935659. External links
"Viltolarsen". Drug Information Portal. U.S. National Library of Medicine (NLM). Clinical trial number NCT02740972 for "Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)" at ClinicalTrials.gov